Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „Median“
Suchtreffer
Begriffe & Kennungen
Docetaxel Kabi · 4.8 · General disorders and administration site conditions The median cumulative dose to treatment discontinuation w
Eintrag öffnenDocetaxel Kabi · 4.8 · General disorders and administration site conditions The median cumulative dose to treatment discontinuation w
Eintrag öffnenEbymect · 4.8 · Diabetic ketoacidosis In the DECLARE study, with a median exposure time of 48 months, events of DKA were repor
Eintrag öffnenEbymect · 4.8 · In the DECLARE study with 17,160 type 2 diabetes mellitus patients and a median exposure time of 48 months, a
Eintrag öffnenEdistride · 4.8 · Diabetic ketoacidosis in type 2 diabetes mellitus In the DECLARE study, with a median exposure time of 48 mont
Eintrag öffnenEdistride · 4.8 · In the DECLARE study with 17,160 type 2 diabetes mellitus patients and a median exposure time of 48 months, a
Eintrag öffnenElahere · 4.8 · The median time to onset for first ocular adverse reaction was 5.1 weeks (range: 0.1 to 68.6). Of the patients
Eintrag öffnenElahere · 4.8 · The median time to onset of peripheral neuropathy was 5.9 weeks (range 0.1 to 126.7). Peripheral neuropathy re
Eintrag öffnenElahere · 4.8 · The median time to onset of pneumonitis was 18.1 weeks (range 1.6 to 97.0). Pneumonitis resulted in mirvetuxim
Eintrag öffnenEminentia medialis
Eintrag öffnenEmtricitabine/Tenofovir disoproxil Krka d.d. · 4.8 · In study GS-US-104-0352, 89 HIV-1 infected paediatric patients with a median age of 7 years (range 2 to 15 yea
Eintrag öffnenEmtricitabine/Tenofovir disoproxil Krka · 4.8 · In study GS-US-104-0352, 89 HIV-1 infected paediatric patients with a median age of 7 years (range 2 to 15 yea
Eintrag öffnenEmtricitabine/Tenofovir disoproxil Mylan · 4.8 · In study GS US 104 0352, 89 HIV-1 infected paediatric patients with a median age of 7 years (range 2 to 15 yea
Eintrag öffnenEmtricitabine/Tenofovir disoproxil Zentiva · 4.8 · In study GS-US-104-0352, 89 HIV-1 infected paediatric patients with a median age of 7 years (range 2 to 15 yea
Eintrag öffnenEnhertu · 4.8 · Left ventricular dysfunction led to treatment interruption in 31/3057 (1.0%) patients. The median time to wors
Eintrag öffnenEnhertu · 4.8 · Left ventricular dysfunction led to treatment interruption in 6/1133 (0.5%) patients. The median time to worst
Eintrag öffnenEntecavir Accord · 4.8 · Treatment beyond 48 weeks: continued treatment with entecavir for a median duration of 96 weeks did not reveal
Eintrag öffnenEntecavir Viatris (previously Entecavir Mylan) · 4.8 · Treatment beyond 48 weeks: continued treatment with entecavir for a median duration of 96 weeks did not reveal
Eintrag öffnenErleada · 4.8 · In the SPARTAN study, with a median exposure of 32.9 months for apalutamide and 11.5 months for placebo, ischa
Eintrag öffnenErleada · 4.8 · In the SPARTAN study, with a median exposure of 32.9 months for apalutamide and 11.5 months for placebo, ischa
Eintrag öffnen